2,355
Views
1
CrossRef citations to date
0
Altmetric
Case Report

An eight-year-old girl with autoimmune polyglandular syndrome type3A that developed during the course of primary Epstein–Barr virus (EBV) infection: clinical implication of EBV in autoimmune thyroid disease

, , , , , , , , ORCID Icon & ORCID Icon show all
Pages 57-60 | Received 16 Apr 2019, Accepted 30 Nov 2019, Published online: 18 Dec 2019

References

  • Ben-Skowronek I, Michalczyk A, Piekarski R, et al. Type III polyglandular autoimmune syndromes in children with type 1 diabetes mellitus. Ann Agric Environ Med. 2013;20(1):140–146.
  • Ascherio A, Munger KL. EBV and autoimmunity. Curr Top Microbiol Immunol. 2015;390(Pt 1):365–385.
  • Takei M, Kitamura N, Shiraiwa H, et al. The possible curative therapy for rheumatoid arthritis–EBV infection control gene SAP and its application. Nihon Rinsho Meneki Gakkai Kaishi. 2008;31(3):141–151.
  • Lombardo F, Messina MF, Salzano G, et al. Prevalence, presentation and clinical evolution of Graves’ disease in children and adolescents with type 1 diabetes mellitus. Horm Res Paediatr. 2011;76(4):221–225.
  • Dost A, Rohrer TR, Frohlich-Reiterer E, et al. Hyperthyroidism in 276 children and adolescents with Type 1 Diabetes from Germany and Austria. Horm Res Paediatr. 2015;84(3):190–198.
  • Greco D, Pisciotta M, Gambina F, et al. Graves’ disease in subjects with type 1 diabetes mellitus: a prevalence study in western Sicily (Italy). Prim Care Diabetes. 2011;5(4):241–244.
  • Oosaki Y, Kawai K, Motohashi S, et al. Type 1 diabetes mellitus and autoimmune thyroid disease in Japan. J Jap Diabetes Society. 2009;52:887–893.
  • Horie I, Kawasaki E, Ando T, et al. Clinical and genetic characteristics of autoimmune polyglandular syndrome type 3 variant in the Japanese population. J Clin Endocrinol Metab. 2012;97(6):E1043–E1050.
  • Morran MP, Vonberg A, Khadra A, et al. Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med. 2015;42:42–60.
  • Nagata K, Nakayama Y, Higaki K, et al. Reactivation of persistent Epstein–Barr virus (EBV) causes secretion of thyrotropin receptor antibodies (TRAbs) in EBV-infected B lymphocytes with TRAbs on their surface. Autoimmunity. 2015;48(5):328–335.
  • Wiersinga WM. Clinical relevance of environmental factors in the pathogenesis of autoimmune Thyroid Disease. Endocrinol Metab. 2016;31(2):213–222.
  • Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet. 2016;387(10035):2340–2348.
  • Rickinson AB, Elliott K. Epstein–Barr Virus. In: Knipe DM, Howley PM, editor. Fields Virology. Philadelphia (PA): Lippincott Williams and Wilkins; 2007. p. 2656–2700.
  • Toussirot E, Roudier J. Epstein–Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol. 2008;22(5):883–896.
  • Bian X, Wallstrom G, Davis A, et al. Immunoproteomic profiling of antiviral antibodies in new-onset type 1 diabetes using protein arrays. diabetes. Diabetes. 2016;65(1):285–296.
  • Thomas D, Karachaliou F, Kallergi K, et al. Herpes virus antibodies seroprevalence in children with autoimmune thyroid disease. Endocr. 2008;33(2):171–175.
  • Mizumoto H, Maihara T, Hiejima E, et al. Transient antiphospholipid antibodies associated with acute infections in children: a report of three cases and a review of the literature. Eur J Pediatr. 2006;165(7):484–488.
  • Akahori H, Takeshita Y, Saito R, et al. Graves’ disease associated with infectious mononucleosis due to primary Epstein–Barr virus infection: report of 3 cases. Intern Med. 2010;49(23):2599–2603.
  • Miyashita K. Three cases of Basedow disease developed in association with unfectious mononucleosis (in Japasese). J Jap Thyroid Associat. 2011;2:45–47.
  • Nagata K, Okuno K, Ochi M, et al. Production of thyrotropin receptor antibodies in acute phase of infectious mononucleosis due to Epstein–Barr virus primary infection: a case report of a child. Springerplus. 2015;4(1):456.
  • Janegova A, Janega P, Rychly B, et al. The role of Epstein–Barr virus infection in the development of autoimmune thyroid diseases. Endokrynol Pol. 2015;66(2):132–136.
  • Nagata K, Higaki K, Nakayama Y, et al. Presence of Epstein–Barr virus-infected B lymphocytes with thyrotropin receptor antibodies on their surface in Graves’ disease patients and in healthy individuals. Autoimmunity. 2014;47(3):193–200.
  • Nagata K, Kumata K, Nakayama Y, et al. Epstein–Barr virus lytic reactivation activates b cells polyclonally and induces activation-induced cytidine deaminase expression: a mechanism underlying autoimmunity and its contribution to graves’ disease. Viral Immunol. 2017;30(3):240–249.
  • Minamitani T, Yasui T, Ma Y, et al. Evasion of affinity-based selection in germinal centers by Epstein–Barr virus LMP2A. Proc Natl Acad Sci USA. 2015;112(37):11612–11617.
  • Dreyfus DH, Nagasawa M, Pratt JC, et al. Inactivation of NF-kappaB by EBV BZLF-1-encoded ZEBRA protein in human T cells. J Immunol. 1999;163(11):6261–6268.
  • Dreyfus DH, Nagasawa M, Kelleher CA, et al. Stable expression of Epstein–Barr virus BZLF-1-encoded ZEBRA protein activates p53-dependent transcription in human Jurkat T-lymphoblastoid cells. Blood. 2000;96(2):625–634.